Literature DB >> 22607700

GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.

Hiroshi Miyamoto1, Koji Izumi, Jorge L Yao, Yi Li, Qi Yang, Loralee A McMahon, Nilda Gonzalez-Roibon, David G Hicks, David Tacha, George J Netto.   

Abstract

Although GATA binding protein 3, a zinc finger transcription factor and an estrogen receptor-regulated gene, has recently been suggested as a marker for urothelium, prognostic significance of GATA binding protein 3 expression in bladder tumor remains unclear. We immunohistochemically stained for GATA binding protein 3 in urothelial neoplasm and matched nonneoplastic bladder tissue specimens. GATA binding protein 3 was positive in 125 (86%; 13 [9%] weak, 44 [30%] moderate, and 68 [47%] strong) of 145 bladder tumors, which was significantly lower than in benign urothelium (104/106 [98%]; 3 [3%] weak, 30 [28%] moderate, and 71 [67%] strong) (P=.001). Fifty (98%) of 51 low-grade tumors were GATA binding protein 3 positive, whereas 75 (80%) of 94 high-grade carcinomas were GATA binding protein 3 positive (P=.002). Similarly, 78 (98%) of 80 non-muscle-invasive tumors expressed the GATA binding protein 3, compared with 47 (72%) of 65 muscle-invasive tumors (P<.001). Conversely, among 68 cases treated with cystectomy, significantly lower expression of GATA binding protein 3 was found in pN0 tumors (32/47 [68%]) than in node-positive tumors (20/21 [95%]) (P=.027). Kaplan-Meier and log-rank tests further revealed that overall positivity (P=.048) or strong positivity (P=.025) of GATA binding protein 3 correlated with progression of muscle-invasive tumors. Multivariate analysis identified high GATA binding protein 3 expression as a strong prognosticator for progression (P=.052) and cancer-specific survival (P=.040) of muscle-invasive tumors. Moreover, there were significant correlations between GATA binding protein 3 expression vs androgen receptor overexpression, estrogen receptor α overexpression, or loss of estrogen receptor β expression. Thus, compared with benign urothelium, a significant decrease in the expression of GATA binding protein 3 in urothelial neoplasms was seen. Loss of GATA binding protein 3 was associated with high-grade and/or muscle-invasive tumors, whereas strong expression was an independent predictor of poor prognosis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22607700     DOI: 10.1016/j.humpath.2012.02.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  23 in total

1.  Loss of GATA3 in bladder cancer promotes cell migration and invasion.

Authors:  Yi Li; Hitoshi Ishiguro; Takashi Kawahara; Eiji Kashiwagi; Koji Izumi; Hiroshi Miyamoto
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

2.  GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens.

Authors:  Yi Li; Hitoshi Ishiguro; Takashi Kawahara; Yurina Miyamoto; Koji Izumi; Hiroshi Miyamoto
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

3.  HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.

Authors:  Justine Varinot; Olivier Cussenot; Morgan Roupret; Pierre Conort; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; Liang Cheng; Eva Compérat
Journal:  Virchows Arch       Date:  2013-10-22       Impact factor: 4.064

4.  GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.

Authors:  Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Janusz Rys; Piotr Czapiewski; Krzysztof Wazny; Renata Langfort; Piotr Waloszczyk; Wojciech Biernat; Jerzy Lasota; Zengfeng Wang
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

5.  GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma.

Authors:  Meenatai Naik; B Vishal Rao; Daphne Fonseca; S Sudha Murthy; Ashwin Giridhar; Rakesh Sharma; Kvvn Raju; T Subramanyeswar Rao; Sundaram Challa
Journal:  Indian J Surg Oncol       Date:  2020-01-18

6.  Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1.

Authors:  Takashi Kawahara; Eiji Kashiwagi; Hiroki Ide; Yi Li; Yichun Zheng; Yurina Miyamoto; George J Netto; Hitoshi Ishiguro; Hiroshi Miyamoto
Journal:  Oncotarget       Date:  2015-01-30

7.  Decreased expression of the GATA3 gene is associated with poor prognosis in primary gastric adenocarcinoma.

Authors:  Rajiv Prasad Keshari; Wei Wang; Yu Zhang; Dan-dan Wang; Yuan-fang Li; Shu-qiang Yuan; Hai-bo Qiu; Chun-yu Huang; Yong-ming Chen; Jian-chuan Xia; Zhi-wei Zhou
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

8.  Downregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder.

Authors:  Yi-Ying Lee; Chieh-Tien Wang; Steven Kuan-Hua Huang; Wen-Jeng Wu; Chun-Nung Huang; Ching-Chia Li; Ti-Chun Chan; Peir-In Liang; Chung-Hsi Hsing; Chien-Feng Li
Journal:  J Cancer       Date:  2016-10-25       Impact factor: 4.207

9.  Transactivation of human osteoprotegerin promoter by GATA-3.

Authors:  Shyan-Yuan Kao; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2015-07-28       Impact factor: 4.379

Review 10.  Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor.

Authors:  Hiroki Ide; Hiroshi Miyamoto
Journal:  Dis Markers       Date:  2015-12-07       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.